rediff.com

Bajaj Healthcare Gets DCGI Nod for Generic Parkinson's Drug

Share on:

By Rediff Money Desk, New Delhi   Jan 30, 2025 15:54

Bajaj Healthcare receives DCGI approval to manufacture Pimavanserin, a generic medication for treating hallucinations and delusions associated with Parkinson's disease.
New Delhi, Jan 30 (PTI) Bajaj Healthcare on Thursday said it has received approval from the Drug Controller General of India (DCGI) to manufacture a drug for the treatment of hallucinations and delusions associated with Parkinson's disease.

The company has received approval to produce both the API and drug formulation of Pimavanserin, a 34 mg capsule.

It is an atypical antipsychotic used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Pimavanserin, marketed globally as Nuplazid, has become a preferred treatment in the US antipsychotic segment.

In a recent update, Acadia Pharmaceuticals announced that Nuplazid, along with its other brand Daybue, is projected to generate more than USD 1 billion in net sales in 2025.

"The growing success of Nuplazid in the US underscores the global demand for this innovative therapy, and we are confident that its introduction in India will be a transformative advancement in the antipsychotic segment," Bajaj Healthcare Managing Director Anil Jain said.

The company said it has also extended offer for Pimavanserin to several leading Indian pharmaceutical companies, ensuring the product's availability in the domestic market.

Shares of the company were trading 2.89 per cent down at Rs 637.40 apiece on BSE.
Source: PTI
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.

TODAY'S MOST TRADED COMPANIES

  • Company Name
  • Price
  • Volume

More »

Moneywiz Live!